Acyclovir 200 mg Oral Tablet
RxNorm 199524
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 199524 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: acyclovir 200 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCD
Semantic Clinical Drug (SCD):
Acyclovir 200 mg Oral Tablet
(Atom ID: 12324742)
SY
Synonym (SY):
Aciclovir 200 mg oral tablet
(Atom ID: 9248429)
PSN
Prescribable Name (PSN):
Acyclovir 200 mg Oral Tablet
(Atom ID: 6368548)
PT
Designated preferred name (PT):
Acyclovir 200 mg oral tablet
(Atom ID: 9248448)
SY
Synonym (SY):
Acycycloguanosine 200 mg Oral Tablet
(Atom ID: 3852116)
FN
Full form of descriptor (FN):
Product containing precisely aciclovir 200 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 10308841)
Patient Education
Acyclovir
Acyclovir is used to decrease pain and speed the healing of sores or blisters in people who have varicella (chickenpox), herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past), and first-time or repeat outbreaks of genital herpes (a herpes virus infection that causes sores to form around the genitals and rectum from time to time). Acyclovir is also sometimes used to prevent outbreaks of genital herpes in people who are infected with the virus. Acyclovir is in a class of antiviral medications called synthetic nucleoside analogues. It works by stopping the spread of the herpes virus in the body. Acyclovir will not cure genital herpes and may not stop the spread of genital herpes to other people.
[Learn More]
* Please review the disclaimer below.